Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxReal-World Depression, Anxiety, and Safety Outcomes of Intramuscular Ketamine Treatment

In this study involving 452 patients with diagnoses of MDD, GAD, and PTSD, IM ketamine reduced depression by 38% and anxiety by 50%, with persistence over 7 months of maintenance therapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form